Brand Name | Status | Last Update |
---|---|---|
empliciti | Biologic Licensing Application | 2022-03-22 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Aging | D000375 | GO_0007568 | R41.81 | — | — | 1 | — | — | 1 |
Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 1 | 1 | — | — | 1 |
Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 6 | 6 | — | — | — | 6 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 5 | — | — | — | 5 |
B-cell lymphoma | D016393 | — | — | 2 | 2 | — | — | — | 2 |
Leukemia | D007938 | — | C95 | 2 | 2 | — | — | — | 2 |
Lymphoid leukemia | D007945 | — | C91 | 2 | 2 | — | — | — | 2 |
Follicular lymphoma | D008224 | — | C82 | 2 | 2 | — | — | — | 2 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 1 | — | — | — | 1 |
Arthritis | D001168 | EFO_0005856 | M05-M14 | — | 1 | — | — | — | 1 |
Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 1 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Esthetics | D004954 | — | — | — | — | — | — | 1 | 1 |
Septic shock | D012772 | — | A48.3 | — | — | — | — | 1 | 1 |
Drug common name | Veltuzumab |
INN | veltuzumab |
Description | Veltuzumab (humanized mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1743088 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | BPD4DGQ314 (ChemIDplus, GSRS) |